ClinicalTrials.gg
CompletedNCT06921590Updated Jul 29, 2026

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

A Phase 1 interventional study of AL001 and Lithium Carbonate Capsule in Pharmacokinetics and Neurology, sponsored by Alzamend Neuro, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Alzamend Neuro, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The goal of this clinical trial is to assess the safety and effects of a crystalized form of lithium, AL001, when compared to commonly used Lithium Carbonate in healthy volunteers. The main questions this study aims to answer are:

How safe and effective is AL001 when compared to Lithium Carbonate? How is AL001 broken down in the brain and body compared to Lithium Carbonate?

Participants will be asked to:

  • Take both the study drug (AL001) and Lithium Carbonate each for a period of 14 days
  • Stay overnight at MGH's research unit for two separate 2-week periods
  • Participate in two separate 24 hour periods of multiple MRIs and blood draws
Read the detailed description

This study is researching the effects of a new type of crystalized lithium, AL001, on it's ability to reach the brain and have an effect. The investigators will be comparing this to a commonly used type of lithium, lithium carbonate. Investigators want to see if the crystalized lithium can have the same or better effect when compared to lithium carbonate. Past research has shown a greater effect within the body with crystalized lithium when compared to commonly used lithium.

This past research suggests that crystallized lithium may be more effective, potentially allowing for lower doses and fewer side effects. If successful, this new form of lithium could offer a new and safe treatment option for psychiatric and neurological disorders.

This study involves two, 2-week long overnight stays at the main campus of Massachusetts General Hospital. During these stays participants will receive lithium carbonate for one stay and the crystalized lithium for the other. There are frequent blood draws and brain MRI scans during two periods of the study to look at how the crystalized lithium is broken down in the body and to see how it reaches the brain. This study will compare AL001 to a study reference treatment of lithium carbonate. The majority of the blood draws and MRIs will occur over a 24 hour period during each 2-week long overnight stay at MGH.

02

Conditions studied

  • Pharmacokinetics
  • Neurology

Keywords

  • Healthy Controls
03

In context

Lead sponsor

Alzamend Neuro, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects ≥18 and \<65 years old in reasonably good physical and psychological health as determined by the Investigator's review of medical and surgical history, physical examination (including neurological examination), 12-lead , vital signs, and clinical laboratory tests.
  2. Assessment of subject's mental health status will be conducted to avoid enrolling subjects who are on the verge of a manic or depressive episode. Affective stability, defined by a Young Mania Rating Scale (YMRS) rating of \<8 and a Hamilton Depression Rating Scale (HRSD-17) rating of ≤7 at screening and baseline. Assessment of subject's suicidal ideation and behavior (SI/B) using the Columbia-Suicide Severity Rating Scale (C SSRS) will be conducted to avoid enrolling subjects with concerning results, defined as a lifetime history of a suicide attempt, past year level 4 or higher suicidal ideation on the C-SSRS, or past month suicidal ideation of any kind. The "Lifetime/Recent" version will be used at screening and the "Since Last Visit" version will be used subsequently.
  3. Able to understand and follow instructions during the study as determined by the Investigator.
  4. Willing to follow study procedures.
  5. Willing and able to adhere to study restrictions and to be confined at the clinical research center per protocol requirements.
  6. Any gender, race, or ethnicity.
  7. Able to understand and provide written .
  8. Males (non-vasectomized and vasectomized) must agree to use barrier during the study until after Treatment Period 2 in-clinic follow-up visit on Day 23 (P2).
  9. Females must meet one the of the following criteria:

    Is of and agrees to use an acceptable contraceptive method. Acceptable contraceptive methods include:

    1. Abstinence from heterosexual intercourse from the Screening visit through to at least 30 days after the last dose of the second study drug on Day 14 (P2).
    2. One of the following highly-effective contraceptive methods, used from at least 28 days prior to the Screening visit through to at least 30 days after the last dose of the second study drug on Day 14 (P2).

      • i. Systemic contraceptives (combined birth control pills, injectable/implant/ insertable hormonal birth control products, or transdermal patch).
      • ii. Intrauterine device (with or without hormones).
      • iii. Male partner vasectomized at least 6 months prior to the Screening visit.
    3. One of the following double-barrier contraceptive methods, used from the Screening visit through to at least 30 days after the last dose of the second study drug on Day 14 (P2):

      • i. Male condom used simultaneously with diaphragm plus spermicide.
      • ii. Male condom used simultaneously with cervical cap plus spermicide.

    Or

    Is of non-childbearing potential, defined as surgically sterile (i.e., has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation), or is in a state (i.e., at least 1 year without menses prior to the Screening visit).

  10. Able to communicate in English, including speaking, reading, and writing.
  11. (BMI) within 18.0 to 30.0 kg/m2, inclusive, and body weight of at least 50 kg at the time of Screening.
  12. ECG recording, after at least 5 minutes of rest in a supine position without abnormalities as determined by the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. abnormalities detected by medical history, physical examination, vital sign measurements, findings, or clinical laboratory findings (as determined by the Investigator) that may affect the safety or successful participation of the subject. Specifically, evidence of clinically significant hematological, renal, endocrine, pulmonary, cardiovascular, dermatologic, muscular, or allergic disease or disorder (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) that may affect the safety or successful participation of the subject. Any history of drug , asthma (with the exception of childhood asthma), urticaria or other severe allergic diathesis.
  2. Presence or history of any disorder that may prevent the successful completion of the study.
  3. Other severe acute, chronic, or historical medical or psychiatric condition or laboratory abnormality or social circumstance that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
  4. History of seizure disorder and/or severe head trauma (other than a single childhood febrile seizure).
  5. History or presence of gastrointestinal disease including chronic gastritis, peptic ulcers, inflammatory bowel disease, hemorrhagic gastritis, or duodenitis.
  6. History or presence of acute or chronic liver disease as determined by the Investigator.
  7. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the study treatments.
  8. Any history of frequent headache or migraine.
  9. Kidney disease ( \<60 mL/minute/1.73 m2).
  10. Uncontrolled tachy/brady arrhythmias, atrial fibrillation, or coronary heart failure.
  11. Systemic related exclusions:

    1. Active cancer (except squamous cell and basal skin cancers) requiring chemo- or radiation therapy.
    2. Positive test results for , , or (unless quantitative PCR negative for HCV) at Screening.
    3. Uncontrolled hypertension with a sustained blood pressure >160/100 mmHg at Screening, or at check-in on Day -1 (P1).
    4. Fever (body temperature >101.4°F [38.5°C]), acute upper respiratory, or any other infections at Screening, or at check-in on Day -1 (P1).
  12. Psychiatric or neurological illnesses (e.g., depression, schizophrenia or other psychotic syndromes, Parkinson's disease and related movement disorders, seizure disorder, and myasthenia gravis).
  13. Treatment with haloperidol, antipsychotics, monoamine oxidase inhibitors, neuromuscular blocking agents. Subjects who have ever received treatment (excluding topical or oral taken 1 and 5 years before Screening, respectively).
  14. Current and during Lithium treatment hyponatremia, defined as serum sodium laboratory value outside the standard reference range.
  15. The use of any medication on a chronic basis with the exception of hormonal for females of . An appropriate drug free period will be required for prescription or over the counter (OTC) drugs to washout, particularly of any especially long half-life drugs (see exclusion criteria 16 and 17 below for relevant details).
  16. The use of any medication (OTC, prescription medication, vitamins, and herbal supplements) within 14 days prior to the Screening visit and 14 days prior to Day -1 (P1) - or at least 6 times the respective elimination half-life rather than 14 days, whichever is longer - through the completion of the second study drug treatment on Day 14 (P2). Contraception may be continued. Acetaminophen may be concomitantly used at the discretion of the Investigator (up to 1000 mg TID). Non-medicated opthalmic products (for lubrication and comfort) may also be permitted at the discretion of the Investigator.
  17. Prescribed or OTC use of a salicylate-containing product other than low dose aspirin for cardioprotection (e.g., aspirin, magnesium salicylate, bismuth sub-salicylate, salicylazosulfapyridine [sulfasalazine]) from 1 week before first dose of the first study drug on Day 1 (P1) to 1 week after last dosing of the second study drug on Day 14 (P2); any other prescribed anticoagulant medication. (Section 5.7.10).
  18. Unwilling to refrain from consumption of poppy seeds or quinine (tonic water) 48 hours prior to check-in on Day -1 (P1) and throughout the course of the study.
  19. Aspirin/nasal polyposis/asthma syndrome.
  20. Female who is breastfeeding.
  21. Female who is pregnant according to the pregnancy test at Screening or prior to the first dosing of the first study drug on Day 1 (P1); female planning to become pregnant during the study.
  22. History of adverse or hypersensitivity reaction to lithium, aspirin, salicylate, L-proline, or any investigational or reference article .
  23. Drug/alcohol abuse:

    1. History of drug abuse (barbiturate, amphetamine, benzodiazepine, cocaine, opiates and cannabis) within the last 12 months or a positive urine drug screen at Screening or Day -1 (P1).
    2. Admitted alcohol abuse or history of alcohol use that may interfere with the subject's ability to comply with the protocol requirements or positive ethanol (alcohol) test at Screening or Day -1 (P1).
    3. More than moderate current alcohol consumption. Subjects will be advised to consume no more than 2 units of alcohol per day and completely abstain from 72 hours prior to any visit (1 unit is equal to approximately 10 g of pure alcohol, [250 mL] of beer [5%], 1 small glass [100 mL] of wine [12%], or 35 mL of spirits [35%]).
  24. Demonstrating excess xanthine consumption (e.g., ingests more than 5 cups of coffee or equivalent per day). Also, subject is not willing to refrain from xanthine products for 48 hours prior to check-in on Day -1 (P1) until discharge from Period 2 treatment on Day 15 (P2). The subject is not willing to refrain from grapefruit, pomelo, Seville orange products or juice within 14 days prior to check-in on Day -1 (P1) until discharge from Period 2 treatment on Day 15 (P2). Exceptions may be made on a case-by-base basis following agreement by the Principal Investigator and the Sponsor.
  25. Participation in a clinical trial and receipt of an investigational medication within 30 days or 5 half-lives (if known), whichever is greater, prior to the first dose of the current study drug.
  26. History of untreated thyroid dysfunction (due to potential lithium drug-disease interaction).
  27. Screening MRI-related exclusion criteria: intracranial mass, evidence of other anatomical findings that might affect safety or causes of cognitive/behavioral impairment as assessed by a qualified neurologist. Subjects must not have any implantable medical device (e.g., aneurysm clip, vagus nerve stimulator, cardiac pacemaker) or be reliant on a non-removable medical device (e.g., insulin pump) unless that device is certified as MRI compatible. Known intolerability to MRI neuroimaging procedures.
  28. Subjects with any past apparent suicide attempt or suicidal behavior, including those with a lifetime history of suicide attempt(s) or a past year level 4 or higher SI/B or past month SI/B (C-SSRS) of any kind.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Other
    Sequence 1: AL001 then Lithium Carbonate

    Participants take 1050 mg of AL001 TID for 14 days then after a washout period, take 150 mg TID of Lithium Carbonate for 14 days.

    Drug: AL001 · Drug: Lithium Carbonate Capsule

  • Other
    Sequence 2: Lithium Carbonate then AL001

    Participants take 150 mg of Lithium Carbonate TID for 14 days, then after a washout period, take 1050 mg of AL001 TID for 14 days.

    Drug: AL001 · Drug: Lithium Carbonate Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate differences in brain and/or brain structure lithium PK relative to plasma PK for AL001 capsule compared to a lithium carbonate capsule.

    • Brain (and brain structures)-to-plasma ratios between AL001 and lithium carbonate for steady-state PK measures/ parameters.

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state

  2. To evaluate differences in brain and/or brain structure lithium PK relative to plasma PK for AL001 capsule compared to a lithium carbonate capsule.

    Area under the plasma and brain concentration versus time curves (AUC) will be measured.

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state

  3. To characterize AL001 lithium PK under the conditions of this study

    Plasma AUCtau ss = Area under the plasma concentration versus time curve from time zero to the end of the 24-hour 3-dose interval at steady-state

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state

  4. To characterize AL001 lithium PK under the conditions of this study

    Brain AUCtau ss = Area under the plasma concentration versus time curve from time zero to the end of the 24-hour 3- dose interval at steady-state

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  5. To characterize AL001 lithium PK under the conditions of this study

    Plasma Cmax ss = Maximum plasma concentration at steady-state.

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  6. To characterize AL001 lithium PK under the conditions of this study

    Brain Cmax ss = Maximum brain concentration at steady-state

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  7. To characterize AL001 lithium PK under the conditions of this study

    Plasma tmax ss = Time to reach the maximum plasma concentration at steady-state

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state

  8. To characterize AL001 lithium PK under the conditions of this study

    Brain tmax ss = Time to reach the maximum brain concentration at steady-state

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  9. To characterize AL001 lithium PK under the conditions of this study

    Plasma Cmin ss = Minimum plasma concentration at steady-state (if at end-of-24 hour dosing interval: Ctrough

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  10. To characterize AL001 lithium PK under the conditions of this study

    Brain Cmin ss = Minimum brain concentration at steady-state (if at end-of-24 hour dosing interval: Ctrough)

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  11. To characterize AL001 lithium PK under the conditions of this study

    Plasma tmin ss = Time to reach the minimum plasma concentration at steady-state over 24 hours

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  12. To characterize AL001 lithium PK under the conditions of this study

    Brain tmin ss = Time to reach the minimum brain concentration at steady-state over 24 hours

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  13. To characterize AL001 lithium PK under the conditions of this study

    Brain/Plasma AUCtau ss ratio = Ratio of brain/plasma areas under the plasma concentration versus time curve from time zero to the end of the 24-hour 3-dose interval at steady-state

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  14. To characterize AL001 lithium PK under the conditions of this study

    Brain/Plasma Cmax ss ratio = Ratio of brain/plasma minimum concentrations from time zero to the end of the 24-hour 3-dose interval at steady-state.

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  15. To characterize AL001 lithium PK under the conditions of this study

    Brain/Plasma Cmin ss ratio = Ratio of brain/plasma minimum concentrations from time zero to the end of the 24-hour 3-dose interval at steady-state.

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  16. To characterize AL001 lithium PK under the conditions of this study

    Plasma apparent oral clearance (CLoral) = Dose24 hours/Plasma AUCtau ss

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  17. To characterize AL001 lithium PK under the conditions of this study

    Average plasma concentration at steady-state (Css ave plasma) = Plasma 24 h AUCtau ss/24 hours

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  18. To characterize AL001 lithium PK under the conditions of this study

    Average brain concentration at steady-state (Css ave brain) = Brain 24 h AUCtau ss/24 hours

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  19. To characterize AL001 lithium PK under the conditions of this study

    Plasma degree of fluctuation at steady-state (FIplasma ss) = Ratio of plasma (Cmax ss - Cmin ss) to Css ave plasma

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  20. To characterize AL001 lithium PK under the conditions of this study

    Brain degree of fluctuation at steady-state (FIbrain ss) = Ratio of brain 24 h (Cmax ss - Cmin ss) to Css ave brain

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  21. To characterize AL001 lithium PK under the conditions of this study

    Plasma swing 24 h = \[(Cmax ss - Cmin ss)/ Cmin ss \]

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  22. To characterize AL001 lithium PK under the conditions of this study

    Brain swing 24 h = \[(Cmax ss - Cmin ss)/ Cmin ss \]

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  23. To characterize AL001 lithium PK under the conditions of this study

    MRT oral doses (0-24h ss) = Mean Residence Time following oral doses at steady-state (0 to tau, end of 24-hour dosing interval)

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  24. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.

    Proportion of participants with adverse events and serious adverse events

    Time frame: From enrollment to end of follow-up period at Day 42(P2)

  25. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.

    Proportion of participants with abnormal vital signs

    Time frame: From enrollment to Day 23 (P2)

  26. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.

    Proportion of participants with abnormal values and change from baseline reading for each ECG parameter. Individual parameters including heart rate, PR, QT, QTcF, QRS, and RR intervals will be collected.

    Time frame: From enrollment to Day 23 (P2)

  27. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.

    Proportion of participants with abnormal findings on physical exam.

    Time frame: From enrollment to Day 23 (P2)

  28. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.

    Proportion of participants with abnormal values and changes from baseline for each Safety laboratory test (standard hematology, blood chemistry \[clinical chemistry\], urinalysis, and pregnancy test \[for females of childbearing potential only).

    Time frame: From enrollment to Day 23 (P2)

  29. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.

    Proportion of participants with prevalence of plasma lithium concentrations above 1.2 mEq/L

    Time frame: From enrollment to Day 23 (P2)

  30. To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in subjects with bipolar I disorder diagnosis under the conditions of this study.

    Proportion of participants with prevalence of plasma salicylic acid concentrations above 30 mg/dL

    Time frame: From enrollment to Day 23 (P2)

Secondary outcomes

  1. To characterize AL001 salicylic acid PK under the conditions of this study

    Plasma AUCtau ss = Area under the plasma concentration versus time curve from time zero to the end of the 24-hour 3-dose interval at steady-state

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  2. To characterize AL001 salicylic acid PK under the conditions of this study

    Plasma Cmax ss = Maximum plasma concentration at steady-state

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  3. To characterize AL001 salicylic acid PK under the conditions of this study

    Plasma tmax ss = Time to reach the maximum plasma concentration at steady-state

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  4. To characterize AL001 salicylic acid PK under the conditions of this study

    Plasma Cmin ss = Minimum plasma concentration at steady-state (if at end-of-24 hour dosing interval: Ctrough)

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  5. To characterize AL001 salicylic acid PK under the conditions of this study

    Plasma tmin ss = Time to reach the minimum plasma concentration at steady-state over 24 hours

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  6. To characterize AL001 salicylic acid PK under the conditions of this study

    Plasma apparent oral clearance (CLoral) = Dose24 hours/Plasma AUCtau ss

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  7. To characterize AL001 salicylic acid PK under the conditions of this study

    Average plasma concentration at steady-state (Css ave plasma) = Plasma 24 h AUCtau ss/24 hours

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  8. To characterize AL001 salicylic acid PK under the conditions of this study

    Plasma degree of fluctuation at steady-state (FIplasma ss) = Ratio of plasma (Cmax ss - Cmin ss) to Css ave plasma

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  9. To characterize AL001 salicylic acid PK under the conditions of this study

    Plasma swing 24 h = \[(Cmax ss - Cmin ss)/ Cmin ss \]

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  10. To characterize AL001 salicylic acid PK under the conditions of this study

    MRT oral doses (0-24h ss) = Mean Residence Time following oral doses at steady-state (0 to tau, end of 24-hour dosing interval)

    Time frame: From time zero to the end of the 24 hour 3-dose interval at steady state.

  11. Exploring Brain Pharmacodynamics using Magnetic Resonance Spectroscopy

    Magnetic resonance spectroscopy (MRS) techniques will be applied to explore brain metabolism, including possible metabolic similarities/differences between treatments

    Time frame: From Screening (Day 1) to Day 23 (P2)

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Dec 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Apr 10, 2025
StartActual
May 9, 2025
Primary completionActual
Dec 15, 2025
CompletionActual
Dec 15, 2025
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06921590
Lead sponsor
Alzamend Neuro, Inc.
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
May 9, 2025
Primary completion
Dec 15, 2025
Completion
Dec 15, 2025
Last update
Jul 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Latozinemab

Start the discussion